NIKKEI 225
27,311.30 +190.80 (+0.70%) HANG SENG
18,012.15 -75.82 (-0.42%) CRUDE OIL
88.90 +1.14 (+1.30%) GOLD FUTURES
1,721.90 +1.10 (+0.06%) DOW
29,926.94 -346.93 (-1.15%) BTC-GBP
17,961.06 -131.84 (-0.73%)
NVO Mar 2023 90.000 put
| Previous close | 4.4000 |
| Open | 4.4000 |
| Bid | 2.6500 |
| Ask | 4.2000 |
| Strike | 90.00 |
| Expiry date | 2023-03-17 |
| Day's range | 4.4000 - 4.4000 |
| Contract range | N/A |
| Volume | |
| Open interest | 26 |
- Zacks
Will Acquisitions Help Novo Nordisk (NVO) Combat Stiff Rivalry?
Novo Nordisk (NVO) expects new acquisitions to diversify its portfolio of marketed drugs and help combat the stiff competition in the diabetes market.
- Globe Newswire
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 3 October 2022 – On 3 August 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programme in
- Globe Newswire
Once-weekly insulin icodec demonstrates superior reduction in HbA1c in combination with a dosing guide app versus once-daily basal insulin in people with type 2 diabetes in ONWARDS 5 phase 3a trial
Bagsværd, Denmark, 3 October 2022 – Novo Nordisk today announced headline results from the ONWARDS 5 phase 3a trial with once-weekly insulin icodec in people with type 2 diabetes. The ONWARDS 5 trial was a 52-week, open-label efficacy and safety treat-to-target trial investigating once-weekly insulin versus once-daily basal insulin (insulin degludec or insulin glargine U100/U300) in 1,085 insulin-naïve people with type 2 diabetes in a clinical practice setting including fewer trial visits compar
